InspireMD Inc. · NASDAQ:NSPR
InspireMD — Investor Presentation (February 2015)
22 slides from InspireMD's investor presentation, February 2015
Slide 1: InspireMD – NYSE MKT: NSPR February 2015
inspireMD NYSE MKT: NSPR February 2015
Slide 2: Forward Looking Statements
Forward Looking Statements This presenta-on contains “forward-‐looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “an-cipates,” “projects,” “predicts,” “es-mates,” “aims,” “believes,” “hopes,” “poten-al” or similar words. Forward-‐lookin
Slide 3: InspireMD company overview
InspireMD An emerging medical device company developing and commercializing advanced technology for interven5onal cardiology and other vascular procedures NYSE MKT: NSPR Stock Price (2/20/15): 52 Week Range: $0.62 $0.54 -‐ $3.80 Average Volume: 167 K Shares Outstanding (1/16/15): 44 M Market Capita
Slide 4: Investment Highlights
Investment Highlights • 2015 return to revenue growth with improved coronary product for near term international opportunities. • Immediate product portfolio expansion: Carotid RX product with revolutionary design and strong First in Man clinical data. • Operating and financial realignment inline wi
Slide 5: Leadership: Significant Track Records of Success
Leadership: Significant Track Records of Success EXECUTIVE TEAM BOARD OF DIRECTORS Alan Milinazzo, President, CEO & Director Dr. Sol Barer, Chairman • Medtronic • Former Chairman and CEO, Celgene • Boston Scien-fic Alan Milinazzo, President, CEO & Director Craig Shore, CFO • Medtronic • Pfizer • Boston
Slide 6: The Wall Street Journal and press coverage on stroke
THE WALL STREET JOURNAL. inspirelMD U.S. NEWS. Stents Boost Stroke Recovery, Study Finds Using Devices to Pull Clots From Brain Arteries Can Help Patients By THOMAS M. BURTON Using a device to extract blood clots from brain arteries can significantly improve patients’ ability to rebound from a strok
Slide 7: Technology: MicroNet
Technology: MicroNet™ Beyond Stenting: MicroNet Mesh for Embolic Protection MGuard Embolic Protection System Combines stent and embolic protection in a single device • Stent platform provides revascularization benefit • MicroNet then acts as safety net by offering greater surface area coverage to pr
Slide 8: Large Addressable Markets
Large Addressable Markets Expanding the MicroNet™ Platform NVGuard ü $125M Flow Diversion Market ü $550M Aneurysm Market ü Late 2015E CE Mark Planned CGuard™ Submission ü $500M Market ü Neurovascular ü CE Mark Cleared ü Carotid PVGuard ü $1.7B Market ü 2016E CE Mark Planned Submission ü Pe
Slide 9: Coronary MGuard EPS
Coronary MGuard™ EPS Improving AMI Patient Outcomes • Current stents not specifically designed for AMI • Distal embolization occurs in up to 73% of cases* • Majority of AMI market is outside of the U.S. (~60%) • MGuard clinical experience including two randomized trials MASTER I and MASTER II with d
Slide 10: MASTER I & II Pooled: All Cause Mortality
MASTER I & II Pooled: All Cause Mortality at 30 days (743 pa-ents) 5 BMS/DES (n=371) MGuard (n=372) 4 HR: 0.14 [95% CI: 0.02, 1.15] 3 P=0.03 Death (%) 2 1.9% 1 0 0.3% 0 5 10 15 20 25 30 Time in Days 10
Slide 11: Carotid Market Opportunity
Carotid Market Opportunity An Enhanced Minimally Invasive Solution • Standard of care: Open surgery: Carotid EndArterectomy (CEA) • Current stents have not improved on CEA stroke rates (CREST) • Mesh covered stent category has the potential to convert CEA to CAS • CARENET 30-day data show CGuard dev
Slide 12: Carotid Solution
Carotid Solution Emerging Market Opportunity CGuard™ Embolic Prevention System Combines stent and embolic protection in a single device • Stent platform provides revascularization benefits • MicroNet acts as safety net by offering greater plaque scaffolding to prevent prolapse related to late emboli
Slide 13: Positive CGuard FIM Clinical Experience
Positive CGuard™ FIM* Clinical Experience CARENET Design (CARotid Embolic protection using microNET) • 30 Patient Safety and efficacy clinical trial • Prospective, multi-center, multispecialty, non-randomized single arm study • Diffusion weighted MRI follow ups at 48hrs and 30 days for “gold-standar
Slide 14: Carotid CGuard Commercialization Strategy
Carotid CGuard™ Commercialization Strategy Disciplined Product Rollout Plan Q4 2014 – Limited Market Release • Germany, Poland, Switzerland, Belgium, Italy, and Spain • 100+ CGuard cases performed to date from 14 sites • FIM data supports full commercial release Q1/Q2 2015 – International Launch • F
Slide 15: 2015 Return to Growth
2015 Return to Growth Revenue Growth with MGuard™ and NEW CGuard™ RX 15
Slide 16: Robust Pipeline
Robust Pipeline Expanding Indications with MicroNet™ Commercial P MGuard™ Coronary • CE Mark Cleared • 12-month MASTER I • FDA Trial On-Hold Exploring Market Opportunity RGuard™ EPS P CGuard™ RX Commercial • CE Mark Cleared • CARENET I • CARENET US IDE Renal* Carotid Planning Activities • CGuard 2
Slide 17: Neurovascular Market Opportunity
Neurovascular Market Opportunity Innovation Leads Growth The Flow Diversion System The preferred solu5on for unruptured aneurysm treatment • Current designs have sub-optimal trackability and in vessel flexibility • MicroNet meets need to simultaneously manage thrombosis of the aneurysmal sac while p
Slide 18: NVGuard Neurovascular
NVGuard™ Neurovascular Differentiation Yields Increased Utility Our Significant Advantage Over Existing Flow Diverters • MicroNet aperture & size • Low metal to artery ratio • Can be placed in side branches and bifurcations, which is impossible with current technology Total Aneurysm Market Value: $9
Slide 19: PVGuard Peripheral
PVGuard™ Peripheral Enabling a New Solution: Peripheral Embolic Protection The Embolic Prevention System A new stent category as the preferred solution for peripheral intervention • Current stents not specifically designed for embolic protection • Mesh covered stent category emerging as immediate op
Slide 20: Target Milestones
Target Milestones Support & Execute on Growth Initiatives 2015E 2016E 2017E NVGuard CE CARENET I Mark 6M FU Submission CGuard FDA PVGuard PMA Submission CE Mark Submission R&D/Clin/Reg DES Pre Clinical DES CE Mark Submission eMASTER Enrollment Strategic Partnership III Strategic Corporate Partnershi
Slide 21: Investment Summary
Investment Summary • 2015 return to revenue growth with improved coronary product for near term international opportunities. • Immediate product portfolio expansion: Carotid RX product with revolutionary design and strong First in Man clinical data. • Operating and financial realignment inline with
Slide 22: Contact: Alan Milinazzo, CEO and Craig Shore, CFO
Alan Milinazzo, CEO Craig Shore, CFO (888) 776-6804 (888) 776-6804 alanm@inspiremd.com craigs@inspiremd.com